香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 2023年第三季度報告 本公告乃上海昊海生物科技股份有限公司（「本公司」，連同其附屬公司統稱「本集 團」）根據香港聯合交易所有限公司證券上市規則第13.09(2)及13.10B條以及香港 法例第571章證券及期貨條例第XIVA部刊發，旨在向本公司股東及公眾人士提供 本公司最新的財務資料。本公告亦同時在上海證券交易所網站發佈。 茲載列本集團截至2023年9月30日止三個月及九個月未經審計業績（「第三季度報 告」）。第三季度報告所載財務數據乃根據中國企業會計準則編製，且未經審計。 提請本公司潛在投資者及股東注意潛在投資風險。 第三季度報告以中英文版本編製。有任何歧義，概以第三季度報告中文版本為準。 承董事會命 上海 ...

2023 中報 | | 頁數 | | --- | --- | | 公司資料 | 2 | | 中期業績摘要 | 4 | | 管理層討論與分析 | 5 | | 中期簡明綜合損益及其他綜合收益表 | 20 | | 中期簡明綜合財務狀況表 | 22 | | 中期簡明綜合權益變動表 | 24 | | 中期簡明綜合現金流量表 | 25 | | 中期簡明綜合財務報表附註 | 27 | | 其他資料 | 50 | | 釋義 | 59 | | 技術詞彙 | 62 | 目 錄 公司資料 第五屆董事會 執行董事： 侯永泰博士 （主席） 吳劍英先生 （總經理） 陳奕奕女士 唐敏捷先生 （財務總監） 非執行董事： 游捷女士 黃明先生 獨立非執行董事： 郭永清先生 姜志宏先生 蘇治先生 楊玉社先生 趙磊先生 第五屆監事會 監事 劉遠中先生 楊青女士 唐躍軍先生 魏長征先生 宋霄女士 授權代表 黃明先生 趙明璟先生 聯席公司秘書 田敏女士 趙明璟先生 （香港公司治理公會資深會員） 審計委員會 郭永清先生 （主席） 游捷女士 姜志宏先生 蘇治先生 趙磊先生 薪酬與考核委員會 蘇治先生 （主席） 吳劍英先生 黃明先生 郭永清先生 趙磊先生 提 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 截至二零二三年六月三十日止六個月期間之中期業績公告 截至二零二三年六月三十日止六個月期間之中期業績摘要 • 報告期內，本集團共錄得營業收入約人民幣1,305.71百萬元（二零二二年同 期：約人民幣956.27百萬元），較二零二二年同期增加約人民幣349.44百萬 元，增幅約為36.54%。 • 報告期內，本集團研發開支約人民幣101.39百萬元，較二零二二年同期增 加約人民幣24.68百萬元，增幅約為32.17%，本集團研發開支佔收入比重為 7.77%（二零二二年同期：8.02%）。 • 報告期內，本公司普通股權益持有人應佔利潤約為人民幣205.24百萬元（二 零二二年同期：約人民幣71.03百萬元），較二零二 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 2023年第一季度報告 本公告乃上海昊海生物科技股份有限公司（「本公司」，連同其附屬公司統稱「本集 團」）根據香港聯合交易所有限公司證券上市規則第13.09(2)及13.10B條以及香港 法例第571章證券及期貨條例第XIVA部刊發，旨在向本公司股東及公眾人士提供 本公司最新的財務資料。本公告亦同時在上海證券交易所網站發佈。 茲載列本集團截至2023年3月31日止三個月（「報告期」）未經審計業績（「第一季 度報告」）。第一季度報告所載財務數據乃根據中國企業會計準則編製，且未經審 計。提請本公司潛在投資者及股東注意潛在投資風險。 第一季度報告以中英文版本編製。有任何歧義，概以第一季度報告中文版本為準。 承董事會命 ...

Financial Performance - In 2022, the company's revenue reached RMB 2,103,438 thousand, an increase from RMB 1,750,116 thousand in 2021, representing a growth of approximately 20.1%[5] - The gross profit margin for 2022 was 68.8%, down from 72.0% in 2021, indicating a decrease in profitability[5] - The net profit attributable to shareholders was RMB 180,470 thousand in 2022, a decline of 48.7% compared to RMB 352,234 thousand in 2021[5] - The total assets as of December 31, 2022, amounted to RMB 6,892,399 thousand, slightly down from RMB 6,950,356 thousand in 2021[5] - The total liabilities increased to RMB 990,016 thousand in 2022 from RMB 890,070 thousand in 2021, resulting in a debt ratio of 14.4%[5] - The company issued a basic earnings per share of RMB 1.04 for 2022, compared to RMB 2.00 in 2021, reflecting a significant decrease[5] - The company reported a total revenue of RMB 2,103.44 million for 2022, representing an increase of RMB 353.32 million or 20.19% compared to the previous year[8] - Net profit attributable to shareholders was approximately RMB 180.47 million, while the net profit excluding non-recurring gains and losses was about RMB 158.75 million[6] Product Revenue Breakdown - The ophthalmic product line generated revenue of RMB 765.97 million, accounting for 36.42% of total revenue, with a year-on-year growth of 14.16%[9] - Revenue from medical beauty and wound care products reached RMB 744.34 million, representing 35.39% of total revenue, with a significant increase of 61.47% year-on-year[9] - The cataract product line generated revenue of RMB 366.00 million, a decrease of RMB 71.82 million or 16.40% year-on-year[13] - The revenue from myopia prevention and refractive correction products was RMB 377.01 million, an increase of RMB 160.77 million or 74.35% compared to the previous year[13] - The revenue from artificial lenses was RMB 277.15 million, a decrease of 16.26% year-on-year, primarily due to the termination of the distribution agreement with Zhuhai Xiangle Medical Equipment Co., Ltd.[13] - The revenue from other ophthalmic products was RMB 22.96 million during the reporting period[14] - The revenue breakdown for 2022 includes: Hyaluronic Acid at RMB 306.16 million (41.13% of total), hEGF at RMB 149.82 million (20.13%), and RF and laser equipment at RMB 288.36 million (38.74%), with respective growth rates of 27.91%, 17.73%, and 205.52%[21][23] Research and Development - Research and development efforts are being prioritized to innovate new products and technologies to meet market demands[1] - The company has completed clinical trials for its innovative hydrophobic aspheric intraocular lens products and is in the registration application phase[6] - The company aims to maintain its technological leadership by focusing on research and development, as well as collaboration with renowned research institutions[7] - In 2022, the company's R&D expenses amounted to RMB 182.19 million, an increase of RMB 14.59 million or 8.71% compared to the previous year, representing 8.66% of operating revenue[10] - The company has established a comprehensive R&D management system supported by a professional and high-quality R&D team, enhancing its competitive advantage in niche markets[179] - The company applied for 67 new patents and was granted 37 patents during the reporting period, bringing the total to 348 patents, including 100 invention patents, as of December 31, 2022[182] Strategic Initiatives - The company plans to focus on expanding its market presence and enhancing its product offerings in the coming years[1] - Strategic initiatives are being implemented to improve operational efficiency and drive future growth[1] - The company plans to enhance internal resource allocation and improve operational efficiency through the integration of acquired companies[7] - The company is exploring potential mergers and acquisitions to strengthen its competitive position in the industry[1] - The company aims to enhance its core competitiveness through the integration of acquired businesses and the optimization of its product lines[29] Market Position and Competitive Advantage - The company is the largest domestic producer of ophthalmic viscoelastic devices, holding a market share of 50.83% in 2021, up from 45.24% in 2020[11] - The company’s competitive advantages include a strong R&D platform for medical biomaterials and a comprehensive marketing strategy that enhances consumer experience and brand loyalty[22] - The company is expanding its market share and influence in the corneal reshaping lens market through exclusive distribution rights and product diversification[17] Employee and Management Information - The total employee compensation for the group in 2022 was approximately RMB 533.22 million, an increase of about RMB 118.84 million compared to RMB 414.38 million in 2021[40] - The company reported a total employee count of 1,990 as of December 31, 2022[83] - The company has established service contracts for directors and supervisors for a term of three years, subject to termination clauses[76] - The company has arranged appropriate liability insurance for its directors, supervisors, and senior management[80] Corporate Governance - The company has established a governance structure comprising the general meeting of shareholders, the board of directors, the supervisory committee, and the management team[116] - The board of directors consists of 11 members, including 4 executive directors, 2 non-executive directors, and 5 independent non-executive directors as of the end of the reporting period[117] - The company has established various corporate governance policies, including the Articles of Association, rules for shareholder meetings, and internal audit systems[131] - The company emphasizes gender diversity in recruitment, evaluating candidates based on professional qualifications and skills, opposing gender discrimination[129] Environmental, Social, and Governance (ESG) Initiatives - The company achieved a rating of AA in the ESG evaluation of A-share listed companies in China, ranking second in the industry[165] - The company has established an ESG governance structure, including a board of directors, an audit committee, and an ESG working group to ensure effective implementation of ESG strategies and risk management[171] - The company actively identifies and assesses climate change risks in accordance with TCFD guidelines to mitigate adverse impacts[199] - The company has established internal regulations for managing hazardous waste, air emissions, and wastewater to ensure compliance with environmental standards[198] Risks and Challenges - The company faces operational risks related to product quality and safety, which could lead to compensation claims and reputational damage if not managed properly[148] - Regulatory changes in China's healthcare system could increase compliance costs and reduce product demand if the company fails to adapt[149] - The company's growth is partially dependent on the increasing purchasing power and health awareness of Chinese residents, which could be affected by industry-wide slowdowns or public safety incidents[150]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 截至二零二二年十二月三十一日止年度 全年業績公告 | --- | --- | |-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...